Rayo Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 192.20%
- Profit Growth 243.68%
- Ebitda 247.11%
- Net Worth 59.30%
- Total Assets -18.37%
About Rayo Pharma
Rayo Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 October 2018 (Six years and three months 18 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Jigneshkumar Patel, Ashik Sanghvi, and Munir Shah serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33119GJ2018PTC104863
-
Company No.
104863
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Oct 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Rayo Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jigneshkumar Patel
|
Director | 23-Oct-2018 | Current |
|
Ashik Sanghvi
|
Director | 23-Oct-2018 | Current |
|
Munir Shah
|
Director | 23-Oct-2018 | Current |
Financial Performance of Rayo Pharma.
Rayo Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 192.2% increase. The company also saw a substantial improvement in profitability, with a 243.68% increase in profit. The company's net worth Soared by an impressive increase of 59.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rayo Pharma?
In 2023, Rayo Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sanghvi Enterprises Private LimitedAshik Sanghvi is a mutual person
-
Rayo Healthcare Private LimitedMunir Shah is a mutual person
-
Trulexa Wellness Private LimitedMunir Shah is a mutual person
-
Aadi Procon Private LimitedMunir Shah is a mutual person
-
Ratna Infracon Private Limited
Munir Shah is a mutual person
-
Ratna Infraestates Private Limited
Munir Shah is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rayo Pharma?
Unlock and access historical data on people associated with Rayo Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rayo Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rayo Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
